Delft-based OASYS NOW wins Slush 100 competition; wins €1M equity investment

Delft-based OASYS NOW, the EU’s first AI-powered patient recruitment platform, has been announced as the winner of Slush 100 after pitching live on the international summit’s Startup Stage.

The Dutch company wins €1M equity investment from two of Europe’s most prominent early-stage venture funds: General Catalyst and Cherry Ventures. 

Additionally, the company will also get hands-on mentoring from industry leaders to scale up its personalised, patient-centric health platform.

The other two startups that made it made it to the final 3 were Ireland’s Dev Ally (a self-serve digital accessibility platform designed to help organisations tackle compliance) and Montreal-based Mohana (a precision platform to help women reduce the time and effort required to detect, understand, and act on hormonal imbalances).

OASYS NOW: Streamlines trial matching process

Founded by Nima Salami and Sara Okhuijsen, OASYS NOW claims to play a pivotal role in addressing a crucial challenge faced by drug development companies—identifying suitable candidates for clinical trials and research studies.

This is significant for patients with life-threatening chronic and rare diseases who need timely access to new treatment options. 

Currently, the process of matching patients with appropriate treatments is manual, laborious, and inefficient, costing drug research organisations millions of euros and, unfortunately, precious lives every year. 

OASYS aims to revolutionise this process, bringing efficiency to drug development and potentially saving lives by providing timely access to new treatment options.

The company focuses on cardiology, rare diseases, and chronic illnesses. It has created an AI-based platform that helps hospitals, doctors, and research nurses find patients eligible for clinical trials.

The company is building the EU’s first AI-powered Patient Recruitment platform for Clinical Trials. It consists of two main products:

GRIP App: The GRIP app helps users take control of their health data. It provides personal health insights and helps users find clinical trials that match their needs, enabling them to receive treatments more quickly.

ELaiGIBLE Platform: The ELaiGIBLE platform accelerates the process of identifying eligible patients for clinical trials. It reduces the time needed from months to just minutes for hospitals, clinics, and research organisations.